Neurocrine Biosciences, Inc.NBIX
NasdaqGS•Healthcare•Drug Manufacturers - Specialty & Generic
Analyze revenue and earnings growth — the core drivers of long-term shareholder returns.
TTM revenue reached $3.10B, growing 28.6% year-over-year. TTM net income stood at $668.60M (118.6% growth). Quarterly EBITDA was $200.70M and operating income was $193.40M. Consistent revenue and earnings growth are the primary drivers of long-term shareholder returns. Analyze NBIX growth trends across revenue, EBITDA, operating income, and net income.
Revenue and earnings growth across quarters